S1P receptor modulators face uncertain future in Crohn’s disease amid trial setbacks GlobalData Oct 14, 2024 GlobalData’s Ulcerative Colitis Market Forecast expects Zeposia to have sales of $374.2 million worldwide in 2031, compared to…
Bristol Myers Squibb presents data from True North trial of Zeposia (ozanimod) for ulcerative… EP News Bureau Oct 11, 2020 Both primary and all key secondary efficacy endpoints showed statistically significant improvements with oral Zeposia versus…
